Diabetes | Grand Challenge - 2021 World Medical Innovation Forum
May 2–4, 2022

Diabetes | Grand Challenge

Diabetes | Grand Challenge

Thursday, May 20, 2021

9:50 AM – 10:15 AM
Hot Topics

The American Diabetes Association estimates 30 million Americans have diabetes and 1.5 million are diagnosed annually. GCT offers the prospect of long-sought treatment for this enormous cohort and their chronic requirements. The complexity of the disease and its management constitute a grand challenge and highlight both the potential of GCT and its current limitations.

  •  Islet transplantation for type 1 diabetes has been attempted for decades. Problems like loss of transplanted islet cells due to autoimmunity and graft site factors have been difficult to address. Is there anything different on the horizon for gene and cell therapies to help this be successful?
  • How is the durability of response for gene or cell therapies for diabetes being addressed? For example, what would the profile of an acceptable (vs. optimal) cell therapy look like?
Marie McDonnell, MD
  • Chief, Diabetes Section and Director, Diabetes Program, BWH
  • Lecturer on Medicine, HMS
Tom Bollenbach, PhD
  • Chief Technology Officer, Advanced Regenerative Manufacturing Institute
Manasi Jaiman, MD
  • Vice President, Clinical Development, ViaCyte
  • Pediatric Endocrinologist,
Bastiano Sanna, PhD
  • EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
Rogerio Vivaldi, MD
  • CEO, Sigilon Therapeutics
  • Q&A

    10:20 AM – 10:35 AM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA